



**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative (Instr. 3)	2. Conversion Date (Month/Day/Year)	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code (Instr. 8)	V (Instr. 8)	(A) Num (Instr. 3, 4 and 5)	(D) Dir (Instr. 3, 4 and 5)	Date Exercisable (Month/Day/Year)	Expiration Date (Month/Day/Year)	Title of Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Beneficial Ownership (Instr. 4)
<p>1. The price reported for this transaction is the weighted average price of multiple trades at prices ranging from \$20.31 to \$21.30. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.</p> <p>2. The price reported for this transaction is the weighted average price of multiple trades at prices ranging from \$21.31 to \$21.74. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.</p> <p>3. The price reported for this transaction is the weighted average price of multiple trades at prices ranging from \$21.39 to \$22.02. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.</p> <p>4. The price reported for this transaction is the weighted average price of multiple trades at prices ranging from \$21.80 to \$22.15. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.</p>														

**Remarks:**

Remark 1: Edward C. Johnson 3d is a Director and the Chairman of FMR LLC and Abigail P. Johnson is a Director, Chairman, the Chief Executive Officer and the President of FMR LLC. Members of the family of Edward C. Johnson 3d, including Abigail P. Johnson, are the predominant owners, directly or indirectly, of Series B voting common shares of FMR LLC, representing 49% of the voting power of FMR LLC. The Johnson family group and all other Series B shareholders have entered into a shareholders' voting agreement under which all Series B voting common shares will be voted in accordance with the majority vote of Series B voting common shares. Accordingly, through their ownership of voting common shares and the execution of the shareholders' voting agreement, members of the Johnson family may be deemed, under the Investment Company Act of 1940, to form a controlling group with respect to FMR LLC. The address of Edward C. Johnson 3d and Abigail P. Johnson is c/o FMR LLC, 245 Summer Street, Boston, MA 02110. Remark 2: FMR Co., Inc. (FMRC), Pyramis Global Advisors, LLC (PGALLC), and Strategic Advisers, Inc. (SAI), each a direct or indirect wholly-owned subsidiary of FMR LLC and an investment adviser registered under the Investment Advisers Act of 1940, and Pyramis Global Advisors Trust Company (PGATC), an indirect wholly-owned subsidiary of FMR LLC and a bank as defined in Section 3(a)(6) of the Securities Exchange Act of 1934 (Exchange Act), are the beneficial owners of Common Stock of Blueprint Medicines Corp. as a result of acting as investment adviser to various client funds and accounts. FMR LLC, Edward C. Johnson 3d and Abigail P. Johnson have no pecuniary interest in the Common Stock beneficially owned by FMRC, PGALLC, SAI and PGATC. Remark 3: The filing of this statement shall not be deemed to be an admission that, for purposes of Section 16 of the Exchange Act or otherwise, the undersigned are the beneficial owners of any securities reported herein.

[Marc R. Bryant, Duly](#)  
[authorized under Powers of](#)  
[Attorney, by and on behalf of](#)  
[FMR LLC and its direct and](#) 11/30/2015  
[indirect subsidiaries, Edward](#)  
[C. Johnson 3d and Abigail P.](#)  
[Johnson](#)

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**